• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Experience of a medicines reference-pricing model.

作者信息

Rothberg A D, Blignault J, Serfontein C B, Valodia B, Eekhout S, Pels L M

机构信息

Medscheme Integrated Care Division, Medscheme (Pty) Ltd., PO Box 70344, Bryanston, Johannesburg.

出版信息

S Afr Med J. 2004 Mar;94(3):183-8.

PMID:15098277
Abstract

OBJECTIVE

To measure the impact of a medicines reference-pricing programme covering items for which appropriate generic equivalents are available.

DESIGN

The list of covered items was continuously monitored and updated by clinicians and pharmacists employed by Medscheme, and was published as the Medscheme Price List (MPL). Prospective and retrospective analyses of prices of medicines covered by the MPL were carried out and the effect of the programme on expenditure by medical schemes was measured.

RESULTS

The programme had an immediate effect on the rate of medicines inflation after implementation as a result of switching from original or branded products to generic medicines or switching from higher-priced to lower-priced generic equivalents.

CONCLUSION

Over the past few years Managed Care has focused on strategies aimed at reducing utilisation of health care services and/or benefits by members of medical schemes. These strategies have largely been directed at members and health care providers, with little attention paid to suppliers (e.g. the pharmaceutical industry). This study has shown that a supplier-directed strategy has merit and is capable of substantially reducing expenditure on medicines.

摘要

相似文献

1
Experience of a medicines reference-pricing model.
S Afr Med J. 2004 Mar;94(3):183-8.
2
Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?在选定的发展中国家中,将品牌原研药转换为通用等效药物:可以节省多少费用?
Value Health. 2012 Jul-Aug;15(5):664-73. doi: 10.1016/j.jval.2012.04.004. Epub 2012 Jul 11.
3
Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.澳大利亚药品福利计划中最低定价政策及引入品牌(通用)替代的影响。
Pharmacoepidemiol Drug Saf. 2001 Jun-Jul;10(4):295-300. doi: 10.1002/pds.603.
4
The effect of generic competition on the price of brand-name drugs.仿制药竞争对品牌药价格的影响。
Health Policy. 2004 Apr;68(1):47-54. doi: 10.1016/j.healthpol.2003.07.007.
5
Potential savings from generic prescribing and generic substitution in South Africa.南非通过开通用名药处方和进行通用名药替换可能实现的节省。
Health Policy Plan. 1996 Jun;11(2):198-205. doi: 10.1093/heapol/11.2.198.
6
Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.基于参考的定价方案:对药品支出、资源利用和健康结果的影响。
Pharmacoeconomics. 2002;20(9):577-91. doi: 10.2165/00019053-200220090-00002.
7
The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.参考定价导致改用仿制药对健康结果和医疗保健利用的影响:以新西兰的拉莫三嗪为例。
Appl Health Econ Health Policy. 2014 Oct;12(5):537-46. doi: 10.1007/s40258-014-0110-0.
8
The maximum medical aid price programme. A review of the concept and of its ability to reduce expenditure on medicines.最高医疗救助价格计划。对该概念及其降低药品支出能力的综述。
S Afr Med J. 1990 Aug 4;78(3):147-51.
9
Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.非专利药进入市场是否降低了澳大利亚药品的购买价格?对强制降价政策实施前后的比较。
Aust Health Rev. 2013 Nov;37(5):675-81. doi: 10.1071/AH13024.
10
The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.非甾体抗炎药参考定价对镇痛药使用及成本的影响。
Health Serv Res. 2005 Oct;40(5 Pt 1):1297-317. doi: 10.1111/j.1475-6773.2005.00420.x.

引用本文的文献

1
Implementation of Medicines Pricing Policies in Ghana: The Interplay of Policy Content, Actors' Participation, and Context.加纳药品定价政策的实施:政策内容、行为者参与和背景的相互作用
Int J Health Policy Manag. 2023;12:7994. doi: 10.34172/ijhpm.2023.7994. Epub 2023 Oct 11.
2
Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.撒哈拉以南非洲药品定价政策的实施:系统评价。
Syst Rev. 2022 Dec 1;11(1):257. doi: 10.1186/s13643-022-02114-z.
3
Utilization of over-the-counter analgesics in two private medical insurance schemes in South Africa.
南非两个私人医疗保险计划中非处方镇痛药的使用情况。
Drug Healthc Patient Saf. 2019 Jul 17;11:37-45. doi: 10.2147/DHPS.S194347. eCollection 2019.
4
Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.药品政策:参考定价、其他定价及采购政策的影响
Cochrane Database Syst Rev. 2014 Oct 16;2014(10):CD005979. doi: 10.1002/14651858.CD005979.pub2.
5
Effects of reference pricing in pharmaceutical markets: a review.药品市场参考定价的影响:综述
Pharmacoeconomics. 2011 Jan;29(1):17-33. doi: 10.2165/11537860-000000000-00000.